Amneal Pharmaceuticals Files 8-K on Shareholder Vote
Ticker: AMRX · Form: 8-K · Filed: May 7, 2024 · CIK: 1723128
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
Related Tickers: AMRX
TL;DR
Amneal Pharma had a shareholder vote on 5/2, details TBD.
AI Summary
Amneal Pharmaceuticals, Inc. filed an 8-K on May 7, 2024, reporting on matters submitted to a vote of security holders on May 2, 2024. The filing does not contain details about the specific proposals voted on or their outcomes.
Why It Matters
This filing indicates that Amneal Pharmaceuticals held a shareholder vote, which is a standard corporate governance event. The lack of specific details in this report means further filings may be needed to understand the outcomes.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure about a shareholder vote without immediate financial implications or significant new information.
Key Players & Entities
- Amneal Pharmaceuticals, Inc. (company) — Registrant
- May 2, 2024 (date) — Date of earliest event reported
- May 7, 2024 (date) — Date of report
- 001-38485 (company) — SEC File Number
- 93-4225266 (company) — IRS Employer Identification No.
FAQ
What specific matters were submitted to a vote of Amneal Pharmaceuticals' security holders on May 2, 2024?
The filing does not specify the exact matters submitted for a vote on May 2, 2024, only that such matters were presented.
What was the outcome of the shareholder vote on May 2, 2024?
This 8-K filing does not disclose the results or outcomes of the shareholder vote that occurred on May 2, 2024.
When did Amneal Pharmaceuticals, Inc. file this Current Report (Form 8-K)?
Amneal Pharmaceuticals, Inc. filed this Current Report on Form 8-K on May 7, 2024.
What is the principal executive office address for Amneal Pharmaceuticals, Inc.?
The principal executive offices are located at 400 Crossing Blvd, Bridgewater, NJ 08807.
Is this filing related to a specific financial event or transaction?
No, this filing is specifically related to 'Submission of Matters to a Vote of Security Holders' and does not detail financial events or transactions.
Filing Stats: 579 words · 2 min read · ~2 pages · Grade level 14.7 · Accepted 2024-05-07 16:18:23
Key Financial Figures
- $0.01 — stered Class A Common Stock, par value $0.01 per share AMRX The Nasdaq Stock Market
Filing Documents
- amrx-20240502.htm (8-K) — 90KB
- 0001628280-24-021107.txt ( ) — 214KB
- amrx-20240502.xsd (EX-101.SCH) — 2KB
- amrx-20240502_lab.xml (EX-101.LAB) — 21KB
- amrx-20240502_pre.xml (EX-101.PRE) — 12KB
- amrx-20240502_htm.xml (XML) — 3KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. Amneal Pharmaceuticals, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") on May 2, 2024. Each of the proposals was approved, and each of the director nominees was elected, by the vote of the stockholders at the Annual Meeting as follows: Proposal 1 : To elect the following director nominees to hold office until the 2025 Annual Meeting of Stockholders and until their respective successors are elected and qualified: For Against Abstain Broker Non-Votes Emily Peterson Alva 253,927,467 1,736,375 40,449 24,065,209 Deb Autor 254,054,265 1,609,738 40,288 24,065,209 J. Kevin Buchi 253,532,508 2,069,308 102,475 24,065,209 Jeff George 253,898,828 1,763,854 41,609 24,065,209 John Kiely 253,584,848 2,015,861 103,582 24,065,209 Paul Meister 238,720,752 16,941,409 42,130 24,065,209 Ted Nark 253,943,612 1,499,704 260,975 24,065,209 Chintu Patel 254,283,523 1,100,436 320,332 24,065,209 Chirag Patel 254,065,112 1,379,383 259,796 24,065,209 Gautam Patel 251,712,874 3,732,183 259,234 24,065,209 Shlomo Yanai 254,374,881 1,067,043 262,367 24,065,209 Proposal 2 : To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers: For Against Abstain Broker Non-Votes 254,365,134 1,199,935 139,222 24,065,209 Proposal 3 : To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024: For Against Abstain Broker Non-Votes 279,106,284 624,760 38,456 0
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 7, 2024 AMNEAL PHARMACEUTICALS, INC. By: /s/ Jason B. Daly Name: Jason B. Daly Title: Senior Vice President, Chief Legal Officer and Corporate Secretary